Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ATOS Stock Forecast 2025-2026
$0.80
Current Price
$103.34M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ATOS Price Targets
+869.6%
To High Target of $7.75
+588.1%
To Median Target of $5.50
+400.4%
To Low Target of $4.00
ATOS Price Momentum
+2.6%
1 Week Change
-2.4%
1 Month Change
-34.4%
1 Year Change
-14.9%
Year-to-Date Change
-38.5%
From 52W High of $1.30
+45.3%
From 52W Low of $0.55
📊 TOP ANALYST CALLS
Did ATOS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Atossa is one of their latest high-conviction picks.
Latest ATOS Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ATOS has a bullish consensus with a median price target of $5.50 (ranging from $4.00 to $7.75). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $0.80, the median forecast implies a 588.1% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 869.6% upside. Conversely, the most conservative target is provided by Albert Lowe at Craig-Hallum, suggesting a 400.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ATOS Analyst Ratings
4
Buy
0
Hold
0
Sell
ATOS Price Target Range
Low
$4.00
Average
$5.50
High
$7.75
Current: $0.80
Latest ATOS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ATOS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 22, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.75 |
| Jun 6, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.50 |
| Jun 5, 2025 | Craig-Hallum | Albert Lowe | Buy | Initiates | $4.00 |
| Apr 21, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.25 |
| Mar 26, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $7.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $7.00 |
| Jan 30, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $7.00 |
| Dec 13, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $7.00 |
| Dec 12, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $N/A |
| Dec 9, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $7.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $6.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $6.00 |
| Sep 11, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $6.50 |
| Aug 12, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $6.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $6.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Jun 6, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $6.25 |
| May 14, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| May 13, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $6.00 |
Atossa Therapeutics Inc. (ATOS) Competitors
The following stocks are similar to Atossa based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Atossa Therapeutics Inc. (ATOS) Financial Data
Atossa Therapeutics Inc. has a market capitalization of $103.34M with a P/E ratio of -4.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -48.9%.
Valuation Metrics
Market Cap
$103.34M
Enterprise Value
$46.26M
P/E Ratio
-4.0x
PEG Ratio
-0.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+50.2%
Current Ratio
6.8x
Debt/Equity
0.0x
ROE
-48.9%
ROA
-29.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Atossa Therapeutics Inc. (ATOS) Business Model
About Atossa Therapeutics Inc.
What They Do
Develops innovative treatments for breast cancer.
Business Model
Atossa Therapeutics makes money by developing proprietary therapies for breast cancer and related conditions, with a focus on unmet medical needs. The company creates both oral and topical treatments, aiming to improve patient outcomes and experiences, while also exploring preventive measures for high-risk individuals. Its unique approach includes personalized medicine based on molecular and genetic analysis, which enhances the potential for successful treatment options.
Additional Information
Operating in the biotechnology sector, Atossa Therapeutics is engaged in research and development specifically targeting hormone receptor-positive and triple-negative breast cancers. The company, established in Seattle, Washington, is committed to advancing healthcare solutions and contributing to the pharmaceutical industry by offering innovative therapeutic options that could elevate treatment standards.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15
CEO
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Country
United States
IPO Year
2012
Website
www.atossatherapeutics.comAtossa Therapeutics Inc. (ATOS) Latest News & Analysis
Latest News
Quick Summary
Atossa Therapeutics completed a Type C meeting with the FDA regarding regulatory strategies for (Z)-endoxifen, exploring expedited pathways for breast cancer treatment and prevention.
Why It Matters
Atossa's engagement with the FDA on expedited pathways for (Z)-endoxifen enhances its potential market entry, potentially boosting investor confidence and stock value in the biopharmaceutical sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Insilico Medicine and Atossa Therapeutics published a study on (Z)-endoxifen's potential for treating glioblastoma multiforme, signaling advancements in AI-driven drug discovery.
Why It Matters
The collaboration between Insilico Medicine and Atossa on a study for glioblastoma multiforme could indicate potential breakthroughs, impacting stock performance and investment interest in both companies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Atossa Therapeutics (Nasdaq: ATOS) highlights potential of (Z)-endoxifen for Duchenne Muscular Dystrophy and associated pathologies, supported by recent research and a forthcoming scientific presentation.
Why It Matters
Atossa's (Z)-endoxifen shows potential in treating DMD and related conditions, which could expand its market and drive investor interest as clinical results develop.
Source: PRNewsWire
Market Sentiment:
Neutral
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
25 days ago
Quick Summary
Atossa Therapeutics is advancing its IND filing for (Z)-endoxifen in metastatic breast cancer, targeting a 2026 NDA. Key leadership has been appointed to enhance development and commercialization efforts.
Why It Matters
Atossa Therapeutics' progress on (Z)-endoxifen and FDA interactions signals potential for accelerated commercialization, impacting future revenue and stock performance positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Atossa Therapeutics (Nasdaq: ATOS) will present four abstracts on (Z)-endoxifen at the San Antonio Breast Cancer Symposium from December 9-12, 2025, advancing its breast cancer treatment research.
Why It Matters
Positive developments in (Z)-endoxifen's clinical data could enhance Atossa Therapeutics' market position, potentially driving stock growth and investor interest ahead of the SABCS presentation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Atossa Therapeutics reported positive enrollment trends and data readouts for (Z)-Endoxifen and other therapies for DCIS. Dr. Laura Esserman will discuss related research at a conference.
Why It Matters
Enrollment momentum and promising data on (Z)-Endoxifen could enhance Atossa's credibility and investment potential, especially in the oncology sector, impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ATOS Stock
What is Atossa Therapeutics Inc.'s (ATOS) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Atossa Therapeutics Inc. (ATOS) has a median price target of $5.50. The highest price target is $7.75 and the lowest is $4.00.
Is ATOS stock a good investment in 2026?
According to current analyst ratings, ATOS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ATOS stock?
Wall Street analysts predict ATOS stock could reach $5.50 in the next 12 months. This represents a 588.1% increase from the current price of $0.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Atossa Therapeutics Inc.'s business model?
Atossa Therapeutics makes money by developing proprietary therapies for breast cancer and related conditions, with a focus on unmet medical needs. The company creates both oral and topical treatments, aiming to improve patient outcomes and experiences, while also exploring preventive measures for high-risk individuals. Its unique approach includes personalized medicine based on molecular and genetic analysis, which enhances the potential for successful treatment options.
What is the highest forecasted price for ATOS Atossa Therapeutics Inc.?
The highest price target for ATOS is $7.75 from Edward Woo at Ascendiant Capital, which represents a 869.6% increase from the current price of $0.80.
What is the lowest forecasted price for ATOS Atossa Therapeutics Inc.?
The lowest price target for ATOS is $4.00 from Albert Lowe at Craig-Hallum, which represents a 400.4% increase from the current price of $0.80.
What is the overall ATOS consensus from analysts for Atossa Therapeutics Inc.?
The overall analyst consensus for ATOS is bullish. Out of 5 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.50.
How accurate are ATOS stock price projections?
Stock price projections, including those for Atossa Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 2:03 PM UTC